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Abstract
AIM: To improve the interpretation of fecal immuno-
chemical test (FIT) results in colorectal cancer (CRC) 
cases from screening and referral cohorts. 
METHODS: In this comparative observational study, 
two prospective cohorts of CRC cases were compared. 
The first cohort was obtained from 10 322 average risk 
subjects invited for CRC screening with FIT, of which, 
only subjects with a positive FIT were referred for colo-
noscopy. The second cohort was obtained from 3637 
subjects scheduled for elective colonoscopy with a posi-
tive FIT result. The same FIT and positivity threshold 
(OC sensor; ≥ 50 ng/mL) was used in both cohorts. 
Colonoscopy was performed in all referral subjects and 
in FIT positive screening subjects. All CRC cases were 
selected from both cohorts. Outcome measurements 
were mean FIT results and FIT scores per tissue tumor 
stage (T stage).
RESULTS: One hundred and eighteen patients with 
CRC were included in the present study: 28 cases ob-
tained from the screening cohort (64% male; mean 
age 65 years, SD 6.5) and 90 cases obtained from the 
referral cohort (58% male; mean age 69 years, SD 9.8). 
The mean FIT results found were higher in the refer-
ral cohort (829 ± 302 ng/mL vs  613 ± 368 ng/mL, P  = 
0.02). Tissue tumor stage (T stage) distribution was dif-
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ferent between both populations [screening population: 
13 (46%) T1, eight (29%) T2, six (21%) T3, one (4%) 
T4 carcinoma; referral population: 12 (13%) T1, 22 
(24%) T2, 52 (58%) T3, four (4%) T4 carcinoma], and 
higher T stage was significantly associated with higher 
FIT results (P  < 0.001). Per tumor stage, no significant 
difference in mean FIT results was observed (screening 
vs  referral: T1 498 ± 382 ng/mL vs  725 ± 374 ng/mL, 
P  = 0.22; T2 787 ± 303 ng/mL vs  794 ± 341 ng/mL, P  
= 0.79; T3 563 ± 368 ng/mL vs  870 ± 258 ng/mL, P  = 
0.13; T4 not available). After correction for T stage in 
logistic regression analysis, no significant differences in 
mean FIT results were observed between both types of 
cohorts (P  = 0.10).
CONCLUSION: Differences in T stage distribution 
largely explain differences in FIT results between 
screening and referral cohorts. Therefore, FIT results 
should be reported according to T stage. 
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Colorectal cancer (CRC) is a disease well suited for popu-
lation-based screening. In industrialized countries, CRC is 
one of  the three malignancies with the highest incidence 
and mortality[1,2]. CRC and adenomas can cause lower 
gastrointestinal bleeding, and early detection by guaiac-
based fecal occult blood tests (g-FOBTs) can decrease 
mortality[3-5]. Recently, fecal immunochemical tests (FITs) 
have been found to be superior over g-FOBTs[6-10]. 
Studies on FITs have used different designs, e.g., in 
terms of  populations studied. Screening and referral 
cohorts each have their pros and cons in this respect[6,7]. 
Studies in screening cohorts, consisting of  individuals 
with average-risk for CRC, best reflect the true target 
population. However, in most such studies, only subjects 
who test positive on FIT are referred for colonoscopy, 
which means that sensitivity and specificity cannot be de-
termined directly[6]. In addition, the number of  cases de-
tected, particularly cancers, is usually low. Other designs 
include high risk or referral cohorts. Here, an important 
advantage is that colonoscopy is performed in all patients 
allowing for calculation of  direct sensitivity and specific-
ity[7]. In addition, these studies often yield more cases, al-
lowing for more detailed subgroup analyses[7,11]. 
It has been suggested that conclusions from refer-
ral studies cannot be extrapolated to the screening set-
ting[12,13]. So far, no comparative data have been published 
to verify or falsify this hypothesis, and arguments both 
in favor of, as well as against this hypothesis exist. Due 
to the higher pretest likelihood and presence of  symp-
tomatic individuals included in referral cohorts, the risk 
of  work-up bias exists, limiting extrapolation to popu-
lation-based screening. On the other hand, CRC stage 
distribution has been shown to influence sensitivity of  
blood-based CRC markers[14], and is likely to have a large 
influence on FIT results[15]. Therefore, the aim of  the 
present study was to compare FIT results between sub-
jects with CRC found in either a screening or a referral 
cohort, and determine if  differences can be explained by 
tumor characteristics. 
MATERIALS AND METHODS
Study design
The present study aimed to compare FIT results in CRC 
cases derived from two methodologically different co-
horts. Here, CRC cases with a FIT result ≥ 50 ng/mL 
from both a screening and a referral cohort were com-
pared for mean FIT result, age, sex and tumor stage. 
Both these studies were initiated in the same time period 
in the same country, and both used the same FIT. 
Setting 
Screening population: The screening cohort in this stu-
dy was prospectively selected from June 2006 to February 
2007 by a randomized selection from a Dutch popula-
tion. Details from this study are described elsewhere[6,16]. 
In short, eligible individuals 50-75 years of  age were 
invited by mail to perform either a g-FOBT or a FIT (n 
= 20  623). Participants with a positive test were offered 
colonoscopy in two academic centers. Exclusion criteria 
were institutionalization and bowel symptoms[6]. In the 
current study, only participants enrolled in the FIT arm (n 
= 10  322) were included.
Referral population: The referral cohort in this study 
was derived from a previous and ongoing study on FIT 
performance, and a more detailed description can be 
found elsewhere[7]. In short, from June 2006 to October 
2009, all ambulatory patients (aged ≥ 18 years) scheduled 
for elective colonoscopy in five Dutch hospitals (includ-
ing an academic center and large teaching hospital), were 
selected regardless of  the indication for colonoscopy. Eli-
gible subjects were invited to participate in a prospective 
study on FIT performance. All participants performed a 
FIT before bowel preparation. Until June 2008, subjects 
were invited to perform both a g-FOBT and an FIT[7]. In 
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an ongoing study after that period, subjects were invited 
to perform an FIT only, but twice (on two consecutive 
days). From the latter cohort, the FIT performed 1 d be-
fore colonoscopy was selected for the current study for 
comparability with the screening population. Exclusion 
criteria were hospitalization, colostomy, inflammatory 
bowel disease or total colectomy. 
Outcomes and measurements
FIT: In both cohorts, an identical semi-quantitative FIT 
was used: OC-sensor (Eiken Chemical Co., Tokyo, Ja-
pan). No restrictions for diet or medication in the week 
prior to FIT were given. Participants were educated by 
illustrated and written instructions to sample their feces, 
ensuring that no contamination with water or urine oc-
curred. In the screening population, participants were 
asked not to perform the test if  blood was visible. 
The FIT used in this study consists of  a sampling 
tube, filled with stabilizing buffer. Participants were in-
structed to scrape the probe at different parts of  the 
stool. The amount of  feces that can be inserted into the 
sample bottle is regulated to approximately 10 mg[17]. 
In the referral population, subjects performed the FIT 
within 72 h before colonoscopy, and returned the test 
and informed consent form on the day of  colonoscopy. 
All samples were placed at -5 ℃ on arrival and analyzed 
according to the manufacturer’s instructions within 1 wk, 
or were frozen at -20 ℃. The analyses were performed 
by two experienced technicians, blinded to the clinical 
data[18]. In the screening population, participants were 
instructed to return the test by mail as soon as possible. 
If  the test could not be returned immediately, storage in 
a refrigerator was advised. Again, two specially trained 
technicians who were blinded to the clinical data pro-
cessed all samples. 
All FITs were analyzed with the OC sensor MICRO 
desktop analyzer (Eiken Chemical Co.). The agglutination 
reaction is dependent on the hemoglobin concentration 
in the sample. A prozone effect may occur if  the concen-
tration is too high and the excess amount of  antigen lim-
its agglutination. Measured values can then be higher or 
lower than the actual concentration in the sample[19]. The 
risk of  the prozone effect gradually increases well above 
1000 ng/mL. Therefore, every measurement above 1000 
ng/mL was classified as 1000 ng/mL. The quantitative 
nature of  the test was maintained, because 1000 ng/mL 
is at least 10 times higher than the most usual cut-off  val-
ues between 50 ng/mL and 100 ng/mL. 
Colonoscopy and detected malignancies: Colonos-
copies were performed under conscious sedation with 
midazolam and fentanyl at the discretion of  the endosco-
pist. In both cohorts, all colonoscopies were performed 
or supervised by experienced gastroenterologists. Colo-
noscopy was considered complete if  the cecum was 
intubated with visualization of  the ileocecal valve or the 
appendiceal orifice, or by intubation up to CRC. Incom-
plete colonoscopies were excluded. In addition, subjects 
were excluded in case of  insufficient bowel cleansing, as 
judged by the individual endoscopist. In the screening co-
hort, an incomplete colonoscopy was followed by a sec-
ond colonoscopy with propofol anesthesia. If  necessary, 
a computed tomographic colonoscopy was performed 
followed by a second colonoscopy. If  an incomplete 
colonoscopy in the referral cohort was followed by a 
complete second colonoscopy, virtual colonoscopy or 
x-colon within 6 mo, the results were included in analysis. 
In the screening study, histology of  tissue samples 
obtained during colonoscopy was evaluated by one expe-
rienced pathologist. In the referral cohort, lesions were 
evaluated according to routine procedures. In both stud-
ies, the outcome variable CRC was classified according to 
tissue tumor stage (T stage) of  the TNM-classification (6th 
edition) according to the AJCC cancer staging manual[20]. 
Statistical analysis
The primary aim of  the study was to compare mean FIT 
scores in CRC cases found in the referral and screening 
setting, with and without correction for CRC T stage. For 
analyses, only individuals with CRC and a FIT result ≥ 50 
ng/mL were selected, because this cut-off  value was used 
for colonoscopy referral in the screening population. 
FIT scores do not follow a Gaussian curve. On aver-
age, even after correction for the prozone effect[19], the 
curve is considerably skewed to the left. Logarithmic 
transformation of  the FIT scores allowed for using the t 
test, as a normal distribution was achieved. Multivariate 
logistic regression analysis was used to evaluate which 
variables could explain the differences in FIT scores be-
tween CRC patients found in the screening and referral 
cohorts. In logistic regression analysis, the outcome vari-
able was mean FIT score, and the independent variables 
were population of  origin, T stage, age, and sex. Logistic 
regression analysis was performed both by forward and 
backward selection. 
Statistical analysis was performed with SAS for Win-
dows, version 8.02 (SAS Institute Inc., Cary, NC). Two-sid-
ed P values < 0.05 were considered statistically significant. 
Ethical approval and consent
In both studies, informed consent was obtained from 
all participants. Approval and consent from the screen-
ing arm of  this study was obtained by the Dutch Health 
Council (2005/03WBO, The Hague, The Netherlands, 
www.gezondheidsraad.nl)[6]. In all centers participating in 
the referral arm of  this study, local Medical Ethics Re-
view Board approval was obtained prior to the start of  
the study[7]. 
RESULTS
Participants 
In the screening population, 10  322 subjects were invited 
to FIT sampling. Of  these, 6157 completed and returned 
the test. Five hundred and twenty-six participants were 
scheduled for colonoscopy because the FIT result was ≥ 
50 ng/mL (i.e., positivity rate of  8.5%). In 428 patients, 
colonoscopy was performed, and considered complete in 
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protocol, incomplete or contaminated colonoscopy, or 
missing histology of  lesions found. Therefore, 3014 
individuals who had a complete colonoscopy and histol-
ogy remained for analysis (completion rate colonoscopy 
91%, Figure 1). The indication for colonoscopy was 
evaluation of  symptoms in 57%, screening and surveil-
lance in 38%, and unspecified in 5% (Table 1). The 
positivity rate (≥ 50 ng/mL) was 15.7%. In total, 105 
subjects with CRC were found, of  whom 96 (91.4%) 
had a positive FIT. The sensitivity of  FIT for detection 
of  CRC at cut-off  values of  50 mg/mL, 75 mg/mL and 
100 mg/mL was 91.4%, 90.5% and 89.5%, respectively. 
The respective specificity for these cut-off  values was 
83.7%, 85.7% and 87.0%.
In total, 124 patients with CRC and a positive FIT 
result were found: 28 derived from the screening popu-
lation and 96 from the referral population. From the 
referral population, six cases were excluded because the 
actual T stage could not be determined due to neoadju-
vant radiotherapy or palliative treatment. The mean age 
of  the remaining 90 CRC cases from the referral cohort 
was significantly higher compared with the 28 cases from 
the screening cohort; 69 (SD 9.8) vs 65 (SD 6.5) years, 
respectively (P = 0.04). As expected, the proportion of  
males was higher in both populations and not statistically 
significantly different between the referred and screened 
population (58% and 64%, P = 0.54, Table 1). Other ab-
normalities that might cause (minor) mucosal bleeding in 
the colon in addition to CRC, potentially influencing the 
FIT results were seen in 64% of  the referral and 79% (not 
significant) of  the screening population (Table 2). 
T stage distribution and FIT results
The 28 CRC cases from the screening population had a 
402 (colonoscopy completion rate 94%; Figure 1). In the 
26 cases in which the cecum was not visualized, a second 
complete colonoscopy was performed. In total, 28 cases 
of  CRC were detected. 
In the referral population, 3637 subjects were invited 
for participation. Six hundred and 23 subjects were 
excluded because of  FIT sampling violating the study 
Screening cohort
FIT invitation (n  = 10  322)
Participation (n  = 6157)
FIT ≥ 50 ng/mL [n  = 526 (8.5%)]
Complete colonscopy (n  = 428)
CRC (n  = 28)
No follow-up (n  = 58)
Referral cohort
FIT invitation (n  = 3637)
FIT performance (n  = 3443)
Colonscopy (n  = 3373)
Complete colonscopy (n  = 3075)1
Complete histology (n  = 3014)
FIT ≥ 50 ng/mL [n  = 474 (15.7%)]
CRC (n  = 28)
Exclusion criteria (n  = 194): IBD 
(n  = 176); colostomy (n  = 14); 
potential radiation colitis (n  = 4)
Error in FIT sampling (n  = 70)
Incomplete of contaminated 
colonscopy (n  = 298)
No histology obtained (n  = 61)
Figure 1  Study flow of the screening and referral cohort compared in the present study. 1This includes cases in which an incomplete initial colonoscopy was fol-
lowed by a second complete colonoscopy, virtual colonoscopy or x-colon. FIT: Fecal immunochemical test; CRC: Colorectal cancer; IBD: Inflammatory bowel disease. 
Table 1  Primary indications for colonoscopy
Indication group Indication for colonoscopy n  
Symptomatic/suspect Weight loss     52
Clinical suspicion of diverticulitis     23
Clinical suspicion of IBD     40
Abdominal pain   310
Anemia   174
Hematochezia   418
Altered bowel habits   416
Clinical or radiological suspicion of CRC     49
Colonoscopy for polypectomy     57
Diarrhea   115
Constipation     71
Total 1725
Screening/surveillance Average risk     69
Familial history of CRC   387
Lynch syndrome     42
Polyp surveillance   491
Post CRC surveillance   157
Total 1146
Other Not specified/others   143
Grand total 3014
Primary indications for colonoscopy among 3014 patients included in the 
referral arm of this study in a comparison of fecal immunochemical test 
results in screening and referral colorectal cancer (CRC) cases (exclusion 
criteria used in the referral arm of the study were age < 18 years, 
hospitalization, colostomy, inflammatory bowel disease (IBD) or total 
colectomy). 
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mean FIT score of  613 ng/mL (SD 368 ng/mL), which 
was significantly lower (P = 0.02) than the mean FIT 
score of  the 90 CRC cases from the referral population 
829 ng/mL (SD 302 ng/mL, Table 3). 
The CRC stage distribution was different between the 
populations: early stages were more frequently found in 
the screening population (Figure 2). Of  the 28 cases from 
the screening population, 13 cases were classified as T1 
(46%), eight as T2 (29%), six as T3 (21%) and one as T4 
carcinoma (4%). In the referral population, 12 patients 
had stage T1 tumor (13%), 22 stage T2 (24%), 52 stage 
T3 (58%) and four stage T4 (4%). 
After stratifying mean FIT scores by T stage, none 
of  the tumor stages had a significant difference in FIT 
results (Table 2): T1, P = 0.22; T2, P = 0.79; T3, P = 0.13. 
There was only one T4 case in the screening popula-
tion, therefore, T4 cases were combined with T3 cases. 
Again, for the combined T3 and T4 stage category, no 
significant difference in FIT score was seen between both 
populations (P = 0.19). 
Logistic regression analysis
By univariate analysis, FIT results from the referral co-
hort were significantly higher compared with the screen-
ing cohort (P < 0.01). However, after adding T stage to 
the model, the difference in FIT results lost statistical 
significance (P = 0.10). The P values per T stage were 0.23 
(T1), 0.79 (T2), and 0.11 (T3/T4). By multivariate analysis 
including the variables sex, age, T, N and M stage, only 
T stage (P < 0.001) and (marginally) age (P = 0.05) could 
significantly explain the differences between the screen-
ing and referral cohorts.
DISCUSSION
The current study compared FIT results in individuals 
with CRC from two different prospective study designs, 
i.e., a population-based screening study and a referral 
cohort, to study the uncertainty about the link between 
the results obtained from these kind of  studies. Cases 
of  CRC from the screening cohort were found to have 
significantly lower FIT results compared to those from 
the referral cohort, but after stratifying for tissue tumor 
stage, no difference remained. In the screening cohort, 
75% (21/28) and in the referral cohort only 38% of  
cases had a T1 or T2 tumor (34/90). Logistic regression 
analysis confirmed that not the type of  population, but 
only T stage and to a lesser extent age could explain the 
differences in FIT results of  CRC patients between these 
screening and referral cohorts. 
The results of  this study are relevant for the evalua-
tion of  CRC screening tests and guidance of  future study 
designs. Several studies in screening populations have 
been performed comparing, e.g., FIT with g-FOBT[6,9,12,21]. 
However, despite the large number of  screened individu-
als in these studies, the absolute number of  individuals 
with CRC was relatively low, hampering subgroup analy-
sis. Furthermore, colonoscopy was missing in subjects 
with a negative FIT, impeding calculation of  sensitiv-
ity and specificity. Indeed, for the investigation of  the 
performance of  a screening test like FIT, the ultimate 
prospective study design would contain full colonoscopic 
evaluation of  all participants. However, in a screening 
population, this is considered unethical or unfeasible 
because the capacity and/or funds are lacking. In referral 
populations, FIT negatives do indeed all undergo colo-
noscopy, and in addition, in much less time and at a sub-
stantially lower cost, a much larger number of  CRC pa-
tients can be included. This enables, e.g., more elaborate 
subgroup analysis of  early stage CRC. The present study 
shows that tumor stage is the major contributor to the 
outcomes of  FIT between cohorts. Possible differences 
in characteristics between the cohorts did not have much 
influence on FIT outcomes. It is indicated here that, if  
correction or stratification for CRC tumor stage distribu-
tion is applied, both screening as well as referral cohorts 
can be used to answer several important screening-related 
research questions. Research questions on accuracy of  
screening tests with sufficient power, could therefore ini-
tially be explored using referral populations. In line with 
Tao and colleagues, who found that sensitivity of  blood-
based CRC markers is dependent on tumor stage[14], 
results for test characteristics should be presented per 
tumor stage. By merging results from different sources, 
the strength of  the evidence available will be enlarged.
Some considerations need to be discussed for proper 
interpretation of  the present results. For evaluation of  
sensitivity and specificity, data from referral studies could 
be extrapolated, or the incidence of  interval cancers 
could be used as false negatives. The latter requires inten-
sive follow-up over many years before sensitivity can be 
estimated; time in which tumors may further evolve. Sec-
ond, the number of  screening cases is limited, although 
comparable with other screening studies[9,12,21]. This limits 
the power to determine any existing differences. How-
ever, from Figure 2 and Table 2 it is clear that it is un-
likely that adding more screening cases could change the 
results substantially. Supported by the results from other 
Table 2  Colorectal cancer patient characteristics and 
potential explanations for positive fecal immunochemical test 
results in addition to colorectal cancer
Screening population 
(n  = 28)
Referral population 
(n  = 90)
Male % 64 581
Age (yr, mean ± SD)   65 ± 6.5   69 ± 9.82
Location of CRC (% left sided) 64 62
CRC only (%)   6 (21) 32 (36)
CRC including (%)
Advanced adenomas 16 (57) 14 (16)
Other adenomas   5 (18) 17 (19)
Other polyps 0 (0) 14 (16)
Diverticula 1 (4)   9 (10)
Hemorrhoids 0 (0) 4 (4)
1χ 2 test: P = 0.54; 2t test: P = 0.04. The percentages of other abnormalities 
in addition to colorectal cancer (CRC) in the referral population totaled 
65% due to rounding. The total percentage of CRC cases with additional 
pathology was 64%. 
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studies[13,16,17,22], CRC was considered the major contribu-
tor to the overall FIT results. Still, it cannot be excluded 
that other sources of  bleeding (like minor polyps) could 
have contributed to the overall FIT result. In addition, 
although probably limited considering the moderate tem-
peratures in the Netherlands, time lag between sampling 
and analysis could have influenced FIT results found[23]. 
In this study, the existing difference between both co-
horts could therefore be even less, because time to analy-
sis in the screening cohort was on average somewhat 
longer. Finally, in the screening cohort, no information 
about preoperative radiotherapy was available and there-
fore tumor stage could have been underestimated in a 
few cases. In summary, the correction for other potential 
bleeding sources, time lag to analysis, and radiotherapy 
would even decrease the differences between the referral 
and screening cohorts and therefore support our conclu-
sions.
The present study aimed to compare test performance 
in two study designs, each with pros and cons, knowing 
the essential differences between the two cohorts. It can 
be concluded that T stage reflects the majority of  the dif-
ferences in overall FIT results between the two studied 
cohorts. 
In conclusion, apparent differences in FIT results be-
tween screened and referred CRC patients can be attrib-
uted to tissue tumor stage. Based on these findings, we 
conclude that results from both cohorts could strengthen 
the evidence available. Using referral populations for 
studying FIT, and potentially also new CRC screening 
tests, can be useful to stimulate progress in CRC research. 
Here, sensitivity and specificity should be studied as 
these measures are independent of  the prevalence of  the 
disease[24], and test characteristics should be stratified by 
tumor stage. This will be of  particular benefit in research 
questions that require large numbers of  cases or colo-
noscopy confirmation in all individuals, and do not seek 
predictive values as outcome. 
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Background
Colorectal cancer (CRC) is a disease well suited for population-based screen-
ing. Subjects who test positive on fecal immunochemical tests (FITs) should 
be referred for colonoscopy. FIT performance has been studied in two different 
types of populations. In studies in screening cohorts, only subjects who test 
positive on FIT are referred for colonoscopy. Sensitivity and specificity cannot 
be calculated directly. In addition, the number of cases detected is usually low. 
Designs with referral cohorts do not study average but high-risk individuals. 
However, as colonoscopy is performed in all subjects direct sensitivity and 
specificity can be calculated. In addition, in referral populations, more cases 
are found. The aim of the present study was to compare FIT results between 
subjects with CRC found in a screening and a referral cohort. 
Table 3  Fecal immunochemical test results in patients with colorectal cancer derived from a screening and referral cohort 
according to tissue tumor stage
Population n mean ± SD 25th % Median 75th % P value1
All colorectal cancer cases Screening 28 613 ± 368 283   662 1000 0.02
Referral 90 829 ± 302 709 1000 1000
T1 Screening 13 498 ± 382   79   384   871 0.22
Referral 12 725 ± 374 428 1000 1000
T2 Screening   8 787 ± 303 559   936 1000 0.79
Referral 22 794 ± 341 550 1000 1000
T3 Screening   6 563 ± 368 269   454 1000 0.13
Referral 52 870 ± 258 888 1000 1000
T4 Screening   1 NA NA NA NA NA
Referral   4 793 ± 415 586 1000 1000
1t test after logarithmic transformation because of non-normality of fecal immunochemical test results (ng/mL). All results ≥ 1000 ng/mL were classified 
as 1000 ng/mL. T: Tumor stage; NA: Not available. (i.e., values like mean and median having a single observation are meaningless and a t test cannot be 
performed because no error term can be estimated for a single observation). 
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Figure 2  Colorectal cancer tumor stage distribution in screening (n = 28) and 
referral (n = 90) populations in studies on diagnostic performance of an fecal 
immunochemical test. Difference between screening and referral P < 0.001.
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Research frontiers
FITs detect occult human blood, what might be derived from adenomas or 
CRC. FITs are more sensitive than guaiac fecal occult blood tests, by which 
screening has been shown to decrease CRC-related mortality. However, exact 
FIT characteristics are the subject of debate. 
Innovations and breakthroughs
The present study is the first to compare results obtained from both screening 
and referral populations to gain insight into the comparability of results derived 
from both study designs. It was shown that referral populations have a different 
tumor stage (T stage) distribution compared to screening populations (i.e., a 
higher percentage of high T stage cancers). This was accompanied by higher 
mean FIT results. After correction for T stage, mean FIT results were similar in 
both populations. 
Applications
Apparent differences in FIT results between screened and referred CRC pa-
tients can be attributed to tissue tumor stage. Results from both cohorts could 
strengthen the evidence available. Using referral populations for studying FIT, 
and potentially also new CRC screening tests, can be useful to stimulate prog-
ress in CRC research, when test characteristics are stratified by tumor stage. 
Peer review
This is an important study comparing the appropriate interpretation of FIT in 
screening population and in patients referred for colonoscopy regardless of the 
indication. According to the authors’ conclusion differences in T-stage distribu-
tion largely explained differences in FIT results between screening and referral 
cohorts. Therefore the absolute value of the FIT results should be reported ac-
cording to T-stage.
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